Adjuvant multimodality treatment of rectal cancer Journal Article


Authors: Galloway, D. J.; Cohen, A. M.; Shank, B.; Friedman, M. A.
Article Title: Adjuvant multimodality treatment of rectal cancer
Abstract: It has long been recognized that curative surgery as the sole treatment for rectal cancer yields disappointing results. There is now a growing body of evidence from prospective randomized clinical trials to support the role of adjuvant therapy for patients whose primary tumour has spread through the rectal wall or has associated lymph node involvement. Carefully planned radiation therapy with adequate doses and fields can reduce the risk of locoregional failure. Chemotherapeutic agents delivered either systemically or regionally may also contribute to better disease control and survival. A number of diagnostic and therapeutic issues still need to be addressed in order to use the available adjuvant treatment methods most appropriately. Efforts to refine patient selection, to enhance therapeutic effect and to minimize toxicity are likely to improve the outlook for patients with resectable rectal cancer. Copyright © 1989 British Journal of Surgery Society Ltd.
Keywords: review; fluorouracil; antineoplastic agents; adjuvant therapy; combined modality therapy; vincristine; short survey; rectal neoplasms; rectum cancer; intravenous drug administration; rectal cancer; oral drug administration; semustine; prognosis; human; priority journal; randomized prospective clinical trials
Journal Title: British Journal of Surgery
Volume: 76
Issue: 5
ISSN: 0007-1323
Publisher: Oxford University Press  
Date Published: 1989-05-01
Start Page: 440
End Page: 447
Language: English
DOI: 10.1002/bjs.1800760507
PUBMED: 2660947
PROVIDER: scopus
DOI/URL:
Notes: Review -- Export Date: 14 April 2020 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Alfred M Cohen
    244 Cohen
  2. Brenda M. Shank
    45 Shank